search
Back to results

Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione

Primary Purpose

Diabetes Mellitus, Non-Insulin-Dependent

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Glimepiride
Sponsored by
Sanofi
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Non-Insulin-Dependent

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients must have given their signed informed consent. Males or females between 18 and 80 years old. Female patients must be surgically sterile, post-menopausal, or using an accepted method of birth control (i.e., oral contraceptives, intrauterine device, Norplant® system, Depo Provera®, or a spermicide and condom). Female patients of childbearing potential must have a negative serum pregnancy test and be advised not to become pregnant during the study. At least 1 year history of NIDDM and performing home blood glucose monitoring. Patients must have BMI of > 26 to < 42 kg/m2 at baseline (week 0). Patients must have HbA1C > 7.5% but < 9.5% at screen (week -4). Patients must have evidence of insulin secretory capacity (fasting C-peptide concentration > or equal to 0.27 nmol/l during the stabilization period). Patients must have FPG > 130 mg/dl but < 235 mg/dl prior to (within 48-72 hours) randomization at Visit 1 Week 0. Patients must be receiving as their current diabetic therapy stable doses of metformin (at dose of 1.0-2.5gm/day), or metformin extended release at a maximum dose of 2 gm/day and a half maximum to a maximum dose of thiazolidinedione for at least 3 months. Patients must be able to understand and willing to adhere to and be compliant with the study protocol. Exclusion Criteria: Patients who require insulin therapy or are currently on other sulfonylureas. Patients with a history of hypersensitivity to sulfonylureas. Patients with past history of severe hypoglycemia reaction on their current antidiabetic therapy requiring medical attention. Patients with a history of acute metabolic complications such as hyperosmolar coma or ketonuria. Patients with clinically significant abnormal baseline laboratory values (hematology, blood chemistry or urinalysis) which define a disease or condition, which in the opinion of the investigator may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to participate and complete the study. Should there be a laboratory value which, upon initial screening, is substantially outside the normal range, the test should be repeated. Patients who had an increase in their thiazolidinedione medication within 2 months of entering the study (Visit 0). Patients who had an increase in the metformin medication within 1 month of entering the study (Visit 0). Patients whose body weight has changed more than 2% for patients < 250 pounds or 3% for patients >= 250 pounds, during the 4 week stabilization period when compared to the weight at the screening visit 0 (week - 4). Patients with acute infections. Patients who have received any drug (i.e. a chemotherapy agent) with a well-defined potential for toxicity to a major organ system during the three months prior to the study. Patients with clinically significant renal or hepatic disease (i.e. ALT > 2.5 x upper limit of normal) or gastrointestinal disorders that may interfere with absorption of the study drugs. Patients who are allergic to sulfonamides and excipients. Patients with any history of alcohol or drug abuse. Pregnant or lactating females will be excluded. Patients with a history of psychosis, emotional or intellectual problems that could impair the ability of the patient to participate in the study or to complete the study. Patients who have participated in any investigational study within 30 days prior to Visit 0.

Sites / Locations

  • Dallas Diabetes & Endocrine Center

Outcomes

Primary Outcome Measures

Change in HbA1C from baseline to Week 26.

Secondary Outcome Measures

Incidence of hypoglycemia.

Full Information

First Posted
August 28, 2002
Last Updated
June 18, 2008
Sponsor
Sanofi
search

1. Study Identification

Unique Protocol Identification Number
NCT00044447
Brief Title
Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione
Official Title
A Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Evaluate the Role of the Addition of Amaryl to NIDDM Patients Not Responding to Maximum Dose Metformin and Thiazolidinedione Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
June 2008
Overall Recruitment Status
Completed
Study Start Date
May 2001 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
September 2002 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Sanofi

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to assess the efficacy and safety of Amaryl when added to Metformin and Thiazolidinedione (TZD) in non-insulin dependent diabetes mellitus (NIDDM) patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Non-Insulin-Dependent

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
170 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Glimepiride
Primary Outcome Measure Information:
Title
Change in HbA1C from baseline to Week 26.
Secondary Outcome Measure Information:
Title
Incidence of hypoglycemia.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients must have given their signed informed consent. Males or females between 18 and 80 years old. Female patients must be surgically sterile, post-menopausal, or using an accepted method of birth control (i.e., oral contraceptives, intrauterine device, Norplant® system, Depo Provera®, or a spermicide and condom). Female patients of childbearing potential must have a negative serum pregnancy test and be advised not to become pregnant during the study. At least 1 year history of NIDDM and performing home blood glucose monitoring. Patients must have BMI of > 26 to < 42 kg/m2 at baseline (week 0). Patients must have HbA1C > 7.5% but < 9.5% at screen (week -4). Patients must have evidence of insulin secretory capacity (fasting C-peptide concentration > or equal to 0.27 nmol/l during the stabilization period). Patients must have FPG > 130 mg/dl but < 235 mg/dl prior to (within 48-72 hours) randomization at Visit 1 Week 0. Patients must be receiving as their current diabetic therapy stable doses of metformin (at dose of 1.0-2.5gm/day), or metformin extended release at a maximum dose of 2 gm/day and a half maximum to a maximum dose of thiazolidinedione for at least 3 months. Patients must be able to understand and willing to adhere to and be compliant with the study protocol. Exclusion Criteria: Patients who require insulin therapy or are currently on other sulfonylureas. Patients with a history of hypersensitivity to sulfonylureas. Patients with past history of severe hypoglycemia reaction on their current antidiabetic therapy requiring medical attention. Patients with a history of acute metabolic complications such as hyperosmolar coma or ketonuria. Patients with clinically significant abnormal baseline laboratory values (hematology, blood chemistry or urinalysis) which define a disease or condition, which in the opinion of the investigator may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to participate and complete the study. Should there be a laboratory value which, upon initial screening, is substantially outside the normal range, the test should be repeated. Patients who had an increase in their thiazolidinedione medication within 2 months of entering the study (Visit 0). Patients who had an increase in the metformin medication within 1 month of entering the study (Visit 0). Patients whose body weight has changed more than 2% for patients < 250 pounds or 3% for patients >= 250 pounds, during the 4 week stabilization period when compared to the weight at the screening visit 0 (week - 4). Patients with acute infections. Patients who have received any drug (i.e. a chemotherapy agent) with a well-defined potential for toxicity to a major organ system during the three months prior to the study. Patients with clinically significant renal or hepatic disease (i.e. ALT > 2.5 x upper limit of normal) or gastrointestinal disorders that may interfere with absorption of the study drugs. Patients who are allergic to sulfonamides and excipients. Patients with any history of alcohol or drug abuse. Pregnant or lactating females will be excluded. Patients with a history of psychosis, emotional or intellectual problems that could impair the ability of the patient to participate in the study or to complete the study. Patients who have participated in any investigational study within 30 days prior to Visit 0.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
ICD CSD
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Dallas Diabetes & Endocrine Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States

12. IPD Sharing Statement

Links:
URL
http://www.sanofi-aventis.com
Description
Related Info

Learn more about this trial

Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione

We'll reach out to this number within 24 hrs